SCFAs exert anti-inflammatory effects and maintain intestinal barrier integrity, while also reducing the levels of harmful metabolites such as endotoxins (e.g., LPS) (inulin-based nanopolysaccharides reduce endotoxins by 40% in animal models (248–250)) and alleviating enteritis induced by pro-inflammatory bile acids such as deoxycholic acid (DCA) through the gut microbiota-farnesoid X receptor (FXR) signaling pathway (251, 252). This evidence concerns the gene NR1H4 and enteritis.